口服孟鲁司特钠治疗35例小儿咳嗽变异性哮喘的临床分析

目的探讨口服孟鲁司特钠治疗小儿咳嗽变异性哮喘的临床疗效。方法选择2009年1月～2010年8月某院收治的咳嗽变异性哮喘患儿70例,按随机数字表法分为观察组和对照组,每组35例。两组患儿均给予止咳化痰、抗感染等常规治疗,观察组在此基础上加用孟鲁司特钠。结果观察组总有效率为97.1%(35/35),对照组为71.4%(25/35),差异有统计学意义(P﹤0.05);治疗后两组FEV1、FVC和FEV1/FVC均明显改善(P﹤0.05),观察组改善较对照组差异有统计学意义(P﹤0.05);观察组咳嗽缓解、消失时间均显著早于对照组,差异有统计学意义(P﹤0.05);观察组复发率为5.7%(2/35),对照组为22.7%(8/35),差异有统计学意义(P﹤0.05);两组均未发生不良反应。结论在常规疗法的基础上联合口服孟鲁司特钠治疗小儿咳嗽变异性哮喘能显著提高临床疗效,迅速缓解症状,改善肺功能,减少复发,且无不良反应,值得临床推广应用。

Clinical analysis of Meng Lu oral montelukast sodium in the treatment of 35 cases with infantile cough variant asthma

OBJECTIVE To explore the clinical curative effect of oral Meng Lu montelukast sodium in treatment of children with cough variant asthma. METHODS 70 cases with cough variant asthma were selected from January 2009 to August 2010 in our hospital, and they were randomly divided into observation group and control group. 35 cases were in each group. The two groups were given with antitussive and expectorant to prevent infection. The observation group was given with Meng Lu montelukast sodium. RESULTS In the study group, the total effective rate was 97.1% (35 / 35), and the control group was 71.4% (25 / 35). There was significant difference between them (P﹤0.05); FEV1, FVC and FEV1 / FVC were significantly improved after treatment in the two groups (P﹤0.05), The observation group was significantly greater improvement than the control group (P﹤0.05); The observation group cough relief and vanishing time were significantly earlier than those in the control group. There was significant difference between them (P﹤0.05); The recurrence rate of the observation group was 5.7% (2 / 35), and was 22.7% in the control group (8 / 35). There was singificant difference between the two groups (P﹤0.05); There were no adverse reaction in the two groups. CONCLUSION Conventional therapies combined oral Meng Lu montelukast sodium could significantly improve the efficacy in the treatment of cough variant asthma, rapid relief of symptoms, improve lung function, reduce recurrence, and had no adverse reaction, which is worthy of clinical application.